Loading stock data…
RXST
$7.46+0.06 (+0.84%)
Market OpenUpdated 10:34 AM EDT
RxSight, Inc., a commercial-stage medical technology company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
RxSight, Inc. in the Healthcare sector is trading at $7.40. The stock is currently near its 52-week low of $5.90, remaining 15.7% below its 200-day moving average. Technical signals show neutral RSI of 56 and bullish MACD crossover, explaining why RXST maintains its current current market pressure. The Whystock Score of 50/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Neutral momentum (RSI 56) — price action in range
Long-term trend bearish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$7.46
Potential Upside
5%
Whystock Fair Value$7.84
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Fundamentals
RxSight, Inc., a commercial-stage medical technology company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States. It offers RxSight system that ena...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$305.37M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.21
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-11.70%
Volume
Today's trading volume
77,360
Recent News
How The RxSight (RXST) Narrative Is Shifting After 2026 Guidance And Target Resets
RxSight’s modeled fair value is steady at US$9.93, closely tracking analyst price targets that cluster in the US$9 to US$10 range. Bullish and bearish commentary around the new 2026 revenue outlook, recent target cuts to the high single digits, and a mix of Neutral and Hold ratings all help explain why that target band has stayed tight rather than moving sharply in either direction. As you read on, you will see how these shifting views and model tweaks can help you follow the evolving story...
How The RxSight (RXST) Story Is Shifting With New Guidance And Street Price Targets
RxSight’s latest valuation work includes a small trim in the modeled fair value, from US$10.21 to US$9.93, and fresh Street targets that now cluster around US$9 to US$10. These adjustments sit alongside research that highlights the new 2026 revenue range of US$120m to US$135m, with many firms holding to Neutral or Hold ratings even as some targets move to US$9 or US$10. As you read on, you will see how these shifting targets and views can help you track the evolving RxSight story over...
How The Story Is Shifting For RxSight (RXST) On Guidance Leadership And Valuation
RxSight’s updated valuation work now points to a fair value of US$10.21 per share, compared with the prior US$10.06, giving you a slightly revised anchor for price expectations. That fine tuning lines up with a mixed analyst backdrop, where clustered high single digit targets and mid range ratings reflect how investors are weighing new 2026 guidance, Q4 numbers and leadership changes. Read on to see what is shaping this evolving narrative and how to keep track of the key moving parts. Analyst...
How The RxSight (RXST) Investment Story Is Shifting With New Guidance And CFO Transition
RxSight’s updated fair value estimate has shifted from US$10.17 to US$10.06, a small adjustment that signals a slightly more restrained price target without a major reset. Analysts tying this move to the new 2026 revenue guidance of US$120.0m to US$135.0m, recent Q4 updates, and the CFO transition are largely keeping the stock in neutral territory while they refresh their models. As you read on, you will see how these pieces fit together and what to watch as the RxSight story continues to...
How The RxSight (RXST) Investment Story Is Shifting With New Guidance And CFO Change
RxSight’s blended fair value estimate has edged down to US$10.17 from US$10.39, reflecting a modest recalibration in the latest round of research updates. Analysts are largely sticking with neutral ratings and fine tuning their targets in a tight band, as they weigh softer 2026 revenue guidance against a slightly firmer revenue trajectory for 2025 and a new CFO stepping into the role. Read on to see how you can track these shifting targets and what they might mean for your own view on...